Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

Trial Profile

A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs DS 1205 (Primary) ; Osimertinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 26 Sep 2018 Retrospective analysis of AXL expression by immunohistochemistry will be conducted using tumor tissue collected prior to study treatment, as per trial design presented the 19th World Conference on Lung Cancer.
    • 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
    • 05 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top